Main content area

The combination of hawthorn extract and camphor significantly increases blood pressure: A meta-analysis and systematic review

Csupor, Dezső, Viczián, Réka, Lantos, Tamás, Kiss, Tivadar, Hegyi, Péter, Tenk, Judit, Czumbel, László Márk, Thanyaporn, Sang-ngoen, Gyöngyi, Zoltán, Varga, Gábor, Gerber, Gábor, Pétervári, Erika, Tóth, Barbara
Phytomedicine 2019 v.63 pp. 152984
Crataegus, adults, camphor, cognition, databases, diastolic blood pressure, fruit extracts, guidelines, hypotension, meta-analysis, patients, placebos, randomized clinical trials, statistical analysis, systematic review, therapeutics
A fixed combination of hawthorn and camphor (Korodin Herz-Kreislauf-Tropfen®) has been used in the therapy of hypotension for decades. Although its efficacy was evaluated in clinical trials, these studies have not been critically assessed in meta-analyses.To systematically evaluate the efficacy of a fix combination of camphor and hawthorn extract (Korodin®) on blood pressure and cognition compared to placebo, in a meta-analysis based on randomized controlled trials (RCTs).The meta-analysis was carried out following the PRISMA guidelines, using the PICO format, and it was registered in the PROSPERO register.The Cochrane Central Register of Controlled Trials, PubMed, Embase, and Web of Science databases were searched for relevant studies. Placebo-controlled clinical studies involving adult patients receiving a fix combination of hawthorn extract and camphor were included. No language or publication year restrictions were applied.Four randomized trials including a total of 221 patients were pooled for statistical analysis. According to the present meta-analysis, the fixed combination of hawthorn and camphor significantly increases systolic and diastolic blood pressure compared to placebo (p-values: 0.017 and 0.049, respectively) and had a beneficial, but not statistically significant effect on the cognitive performance in the connect-the-numbers test (p-value: 0.071).Korodin® is an effective and presumably safe complementary therapy for the treatment of hypotension. Its blood pressure increasing effect is confirmed; however, the evidence supporting its use is very limited. The optimum dose and duration of treatment is still unclear. The comprehensive evaluation of efficacy and safety is required in further, high-quality clinical studies, involving larger patient populations and comparable endpoints.